Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

refractory 'aggressive' lymphoma: no limit on prior therapies, relapse <6 months after first dose of RTX-containing therapy ≤2 prior therapies, not refractory to RTX ORR: 80% (relapsed); 20% ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).